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Background: Complementary medicines (CMs) are widely used by the Australian public, and pharmacies are major
suppliers of these medicines. The integration of CMs into pharmacy practice is well documented, but the
behaviours of pharmacists in recommending CMs to customers are less well studied. This study reports on factors
that influence whether or not pharmacists in Australia recommend CMs to their customers.
Methods: Data were collected from semi-structured interviews with twelve practicing pharmacists based in
Brisbane, Australia. The qualitative data were analysed by thematic analysis.
Results: The primary driver of the recommendation of CMs was a desire to provide a health benefit to the
customer. Other important drivers were an awareness of evidence of efficacy, customer feedback and pharmacy
protocols to recommend a CM alongside a particular pharmaceutical medication. The primary barrier to the
recommendation of CMs was safety concerns around patients on multiple medications or with complex health
issues. Also, a lack of knowledge of CMs, a perceived lack of evidence or a lack of time to counsel patients were
identified as barriers. There was a desire to see a greater integration of CM into formal pharmacy education.
Additionally, the provision of good quality educational materials was seen as important to allow pharmacists to
assess levels of evidence for CMs and educate them on their safe and appropriate use.
Conclusions: Pharmacists who frequently recommend CMs identify many potential benefits for patients and see it
as an important part of providing a ‘healthcare solution’. To encourage the informed use of CMs in pharmacy there
is a need for the development of accessible, quality resources on CMs. In addition, incorporation of CM education
into pharmacy curricula would better prepare graduate pharmacists for community practice. Ultimately, such moves
would contribute to the safe and effective use of CMs to the benefit of consumers.
Keywords: Pharmacy and complementary medicine, Pharmacists’ attitude towards complementary medicine,
Pharmacy practice, Companion selling, Qualitative studyBackground
The popularity and use of complementary medicines
(CMs) is increasing in Australia and many other developed
countries. A 2004 study in South Australia found 52.2% of
those surveyed used some form of CM [1], and a 2007 na-
tional survey found that 68.9% of Australians used at least
one form of CM in the previous year [2]. As community
pharmacy is a major provider of CM products, it is also* Correspondence: hans.wohlmuth@scu.edu.au
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distribution, and reproduction in any mediumwhere many consumers seek advice about their use. There
has been limited research, however, into the integration of
CM into pharmacy practice and pharmacists’ ability to
meet their patients’ needs for CM advice [3,4]. According
to a recent survey of pharmacy customers in Australia,
87% expect the pharmacist to be able to recommend
efficacious CMs and 92% expect them to provide informa-
tion relating to the safety of the products [5]. Pharmacists
generally agree that they should provide this information,
but many feel they have insufficient knowledge or education
[4,6-12]. They do however, view CMs as useful – a survey
of 1500 Australian pharmacists found 77% agreed that CMsBioMed Central Ltd. This is an Open Access article distributed under the terms of
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a recent survey of rural Australian community pharmacists
reported that 94% believed they should regularly ask
consumers if they are using CMs [11]. The existing research
investigating the recommendation of CMs by pharmacists
has identified a number of factors that influence this
behaviour. These include an understanding of the benefits
of CMs for maintenance of general health, prevention
of disease and treatment of minor conditions [7,8,13,14],
patient demand [7], personal usage of CM [10,11], know-
ledge of a particular CM product and its proven mechanism
of action [6,7], and the profile of the CM company [7].
Whilst profit is not stated as an important motive [6,7,14,15],
most pharmacists believe they should sell CMs [7], and that
CMs can enhance the image of the pharmacy, increase
annual sales and be an important part of the financial
business of retail pharmacy [6,16]. The major barrier to
the recommendation of CMs by pharmacists is reported
to be a lack of evidence [4,6,11,12,17-20]. Other barriers
include lack of training, lack of accurate and easily accessible
information, lack of subsidies or reimbursement, legal
concerns, time constraints, and the fact that other staff in a
pharmacy may recommend these products [4,14,16,18,20].
This study aimed to explore, through thematic analysis of
semi-structured interviews, what influences a pharmacist to
recommend or not recommend CMs to a customer in a
community pharmacy setting. A better understanding
of these issues may assist in determining the best ways
to facilitate better integration of CM into community
pharmacy practice, which in turn may benefit both
pharmacists and consumers.Methods
In the first stage of recruitment, all pharmacists work-
ing in a pharmacy in the greater Brisbane area with a
current account with CM company Blackmores Ltd.
(comprising approximately 90% of Australian pharma-
cies) were eligible. Potential respondents were con-
tacted by mail and follow up phone call. A second
round of recruitment was initiated from recommenda-
tions of initial respondents (snowball sampling) and from
contacting key personnel in the industry including store
managers and Pharmacy Guild staff. Further recruitment
was conducted by doorknocking local pharmacies. In these
further stages of recruitment, all pharmacists were eligible,
including those without a Blackmores account. The 12
recruited pharmacists were assigned to one of three groups
based on their responses to a questionnaire provided in the
initial information kit. Group assignment was as fol-
lows: Group 1 recommended CMs less than 20 times
per week, Group 2 recommended CMs 20 to 50 times
per week, and Group 3 recommended CMs more than
50 times per week. Where a pharmacist did not workfull-time on the pharmacy floor, assignment was made
on a pro-rata basis.
Data were collected by semi-structured interviews in
locations convenient to respondents, mostly in a private
office in the pharmacy or occasionally in a local coffee
shop. The questions posed led the discussion to cover a
number of areas of interest, namely factors affecting
their recommendation of CMs, family and personal use
of CMs, information sources for CMs, patterns of CM
recommendation, knowledge of CMs, and pharmacy
protocols for the recommendation of CMs. Interviews
were recorded and manually transcribed; written notes
were made of any relevant casual discussion occurring
prior to or after the recorded interview. Respondents
were invited to check the accuracy of the transcript to
ensure it reflected the reality of the interview as they
perceived it and to provide an opportunity to add any
further information.
Thematic analysis [21] of the transcribed interviews
was carried out by the primary investigator (SEC) in
consultation with the other investigator. First the tran-
scripts were read and initial codes assigned. Further analysis
revealed distinct themes relating to the respondents’ back-
ground, education, attitudes to CM and CM recommenda-
tion patterns. This allowed for codes to be clustered into
descriptive categories, each comprising several subcategories.
Data were compared within groups and excerpts selected
which illustrated the categories. Data were then compared
between groups to identify differences and similarities.
All coding, analysis, and interpretation was continuously
compared and reassessed to ensure validity, until theoretical
saturation was reached [21-23].
The study was approved by the Human Research Ethics
Committee of Southern Cross University (approval
number ECN-10-224), and all respondents provided
written, informed consent.Results
A total of 12 pharmacists (five female, seven male, aged
25–60) practising in community pharmacies in the greater
Brisbane area (Queensland, Australia) were interviewed in
April-May 2011. Their tenure in pharmacy ranged from
one-and-a-half years to 36 years. They worked in pharmacies
of varying size, both independent and banner pharmacies
(banner pharmacies are independently owned pharmacies
operating under the same marketing banner) (Table 1).
All respondents had received their pharmacy training from
one of five Australian universities. Two had received some
level of training in CM from private education providers,
and all but two had attended industry-sponsored CM
seminars. A total of seven hours of interviews were
recorded and transcribed (median duration 35 min, range
14–81 min).
Table 1 Details of respondents and their pharmacies
Respondent Years since graduation Pharmacy type† Size of pharmacy CM business*
Group 1 (<20 times/week)
1.1 10 Banner Small
1.2 4 Banner Small
1.3 2 Independent Small
Group 2 (20–50 times/week)
2.1 3 Banner Large
2.2 32 Independent Small
2.3 3 Banner Medium
2.4 7 Banner Large
2.5 7 Banner Small
Group 3 (>50 times/week)
3.1 36 Independent Small
3.2 4 Banner Small
3.3 32 Banner Large
3.4 14 Banner Large
Group 1 respondents recommended CMs <20 times per week, Group 2 respondents 20–50 times per week, and Group 3 respondents >50 times per week.
† Banner pharmacies are independently owned but operate under the same marketing banner.
* Based on annual purchases of products from Blackmores Ltd. Small: <$30,000 Medium: $30,000 - $60,000 Large: >$60,000.
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Six major categories emerged as a result of the data analysis,
each with several subcategories (Table 2).
There was a large degree of inter-group congruence in
responses – with two exceptions. One respondent in
Group 1 expressed a greater amount of knowledge and
acceptance of CM than others in this group, but stated
that they did not recommend CMs extensively, as this
was being done by others – both by a naturopath in the
store and by local doctors, who made a high level of CM
recommendations and directed their patients into the
pharmacy with CM prescriptions. The other exception
was a pharmacist in Group 2, who had extensive training
in CM and was passionate about its benefits. This
respondent stated that the reason for their medium (rather
than high) level of recommendation of CMs was the
conservative demographics of the suburb where the
pharmacy was located.Drivers of the recommendation of CMs
There were a number of subcategories of this category,
especially in Groups 2 and 3, reflecting a wider range of
reasons for recommending CMs in these groups (Table 2).Group 1 (low level of CM recommendation)
The main subcategories in this group were ‘condition-
based recommendation’ and ‘health benefit’ with a lesser
emphasis on ‘customer demand’, ‘company profile’ and
‘cost’.Each Group 1 pharmacist mentioned between one and
four specific CMs and related indications they felt
comfortable with. They all mentioned that they stick to
this narrow range of CMs:
‘B group vitamins to stressed students or professionals.
Glucosamine and fish oils to people with osteoarthritis.
Fish oils to people with hypertension. They are my safe
zones.’
Customer demand was not mentioned as a strong reason
to recommend, except for one respondent who said that if
a customer asked for something in particular, that would
be their primary reason for selling a CM product.
The profile of a company in terms of reputation and
quality of products and services also had some impact
on which products were recommended:
‘Credibility and availability long term are things. . .if
considering three or four companies that look after us
reasonably well, at least in regards to supply, after
that criteria (sic) is met I try to provide value for
customers.’
Responses to whether cost was an issue for them or
their customers varied:
‘I might spend too much time in trying to give value to
people. I’ll walk around to find three brands of fish oil
and give them the cheapest at the time.’
Table 2 Major categories and sub-categories identified in transcribed interviews
Major category Sub-categories




Companion selling and pharmacy protocols






2. Barriers to the recommendation of CMs Safety concerns
Lack of knowledge about safety and efficacy
Lack of evidence
Lack of clear patient benefit
Fad products
Time constraints
3. Attitude to CMs Role for CMs in pharmacy
Responsibility to provide information about CMs
4. Education and resources University training
Work experience
Self-awareness of knowledge level
Information sources
Information needs
5. Personal and family use of CMs Personal use
Use by family members
6. Relationship with other healthcare professionals Medical practitioners
Naturopaths
Thematic analysis of transcripts involved a process of coding and clustering of codes into categories with continuous comparisons and re-assessment to ensure
validity.
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the cost an issue.’
Group 2 (medium level of CM recommendation)
The most consistent motives for CM recommendation
in this group related to health benefits for patients and
companion selling a CM product with a pharmaceutical
medication. Subcategories were ‘condition-based recom-
mendation’, ‘health benefit’, ‘customer demand’, ‘evidence
for efficacy’, ‘companion selling and pharmacy protocols’,
‘profitability’, ‘demographics’, ‘company profile’, ‘ethical
responsibility’ and ‘holistic care’. Cost was mentioned as
a factor in their decisions of which CM to recommend,
but was not seen as a particularly important one.
Each Group 2 pharmacist discussed between four and
ten different CMs they recommended for specificconditions, although they mentioned being comfortable
with many more products:
‘A lot [of my recommendations] would be in the top
twenty, like fish oil, glucosamine, acidophilus, coming
to winter season now, things for the immune system,
olive leaf, that I would usually recommend.’
Subcategories of ‘health benefit’, ‘customer demand’
and ‘evidence for efficacy’ were linked for pharmacists in
this group. They valued clinical evidence, but feedback
from customers also gave them more incentive to recom-
mend CMs:
‘. . .[I’d like to see] the trials that have been done. . .but
also, if the patient takes it and finds it works, you’ve
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it works.’
‘. . .customers and consumers want to have alternative
medicines. They’re actively seeking something else
apart from orthodox medicine, so I guess you just have
to know about them, and as a pharmacist you have to
find whether certain things are evidence based.’
Personal experience of benefit was also described as a
motivator to recommend CMs:
‘I think another thing that would influence me is if I’ve
had personal experience with a product, so for
example if I’ve used something that I’ve found very
useful,. . . and if you tell a customer, “Oh, I’ve used this
product and this is what happened” they are more
receptive to that product.’
All pharmacists in this group described a preference
for a CM over a pharmaceutical medicine in some
instances, and they felt quite comfortable talking to cus-
tomers about this:
‘. . .the one that probably comes to mind most is for restless
legs and cramping. I’ll always pick a calcium-magnesium
instead of a sedating antihistamine to relax the muscles.’
Two respondents mentioned benefits in relation to
insomnia:
‘If they came in with a sleep issue, I’d think about a
natural product first. . .(because of ) side effects,
addictiveness.’
Companion sales and pharmacy protocols were a
major reason to recommend CMs in both Group 2
and 3. All pharmacists in Group 2 described proto-
cols in their workplace to recommend a particular
CM with a particular prescription or over-the-
counter (OTC) medication, either to ameliorate side
effects or to provide an adjunct therapeutic benefit.
The most commonly mentioned combinations were
probiotics with antibiotics, co-enzyme Q10 with
cholesterol-lowering ‘statin’ medications, glucosamine
and/or fish oil with various arthritis medications, and
CMs for cold and ‘flu with OTC products:
‘We have a system where if I’m dispensing a prescription
medicine, lets say a cholesterol-lowering product, we
have tags we put in the basket saying, “Your pharmacist
recommends you take CoQ10” or things like that, so
even if I am busy doing other things, there is some
pharmacist intervention to recommend a product. . .’Respondents who worked in banner pharmacies described
a corporate policy of companion selling:
‘It’s all written down in the [pharmacy group]
protocols, so if you work for [pharmacy group] you’re
expected to follow this.’
The benefits to patients of recommending CMs along
with conventional medicines was clear to respondents in
this group:
‘I’m always in favour of adding something, as long as
it doesn’t interact with other medicines. . . Adding
something into their medication profile just to make
sure they’re getting a little bit of extra help, and. . .
they don’t need to go on another or higher dose
cholesterol tablet, when they can start fish oil instead.’
Whilst they were aware that companion selling was
potentially profitable for the pharmacy, respondents
denied that would be a reason for following a protocol:
‘If there’s an opportunity to companion sell and they
don’t need it, I won’t do it.’
Pharmacists were less likely to recommend CMs when
they worked in a pharmacy in a lower socioeconomic
area. All respondents currently worked in urban or sub-
urban pharmacies; however, those who had previously
worked in regional areas described a greater acceptance
of CM in the city. One respondent mentioned that the
conservative nature of the suburb where their pharmacy
was located influenced recommendation patterns and
made them less likely to recommend in some instances.
Another pharmacist working in an area with a higher
Asian population reported:
‘With the higher Asian population we do sell a lot
more vitamins, compared to where I have been
previously. . . The Asian population seems to be much
more into natural health and vitamins.’
The respondents’ impression of a CM company’s
reputation had some impact on their choice of prod-
uct. They were as a group more comfortable with
brands that were well established and had a larger
portfolio of products:
‘. . .it’s to do with their reputation too. . .they have good
products, they have a good range of products. I’d be
less likely to trust a company that put out one wonder
product and that’s all they have. So larger companies
and more reputable companies I do trust and am
more receptive to their new products.’
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that it was their ethical responsibility in some cases to
recommend CM in order to provide proper care to their
patients. The term ‘holistic’, a term commonly used by
complementary medicine practitioners, was used in
regard to their recommendations a number of times:
‘. . .trying to think holistically how you can improve
their health outcomes. . .that’s one of the main driving
factors for me.’
‘. . .my conscience tells me that I really do need to offer
that [advice on CM] to those people who are really
interested, and also to educate those people who have
been to some degree fobbed off [by orthodox
approaches to medicine].’
Finally, Group 2 pharmacists were aware that when
they recommended a CM, this recommendation was
likely to be taken more seriously because of their status
as a trusted healthcare professional:
‘I think coming from a pharmacist, if I am
recommending a complementary product as opposed
to an assistant, it provides more credibility, trusting
that product, they will give it a go, will be more
compliant to it as well.’
Group 3 (high level of CM recommendation)
Pharmacists in Group 3 had similar reasons for recom-
mending CM to those in Group 2, hence the subcategories
describing these reasons were the same for both groups.
The most common primary motive for recommending
a CM was health outcomes, and whilst they were more
candid than pharmacists in other groups about potential
profitability, they did not describe this as their primary
motive for recommendation of CMs, but rather a beneficial
spin-off of good customer service:
‘Well, [I recommend CM] because it works and your
customer will come back, and you’ve got a happy
customer. A happy customer talking to all their
friends, saying, “this chemist really knows what they’re
talking about” is the best kind of advertising you can
get.’
‘. . .it’s a twofold thing. You’re helping your customer,
and it is important to your pharmacy, so I can’t
understand why pharmacists wouldn’t want it.’
Like Group 2, condition-based recommendations were
frequently mentioned, and the number of CMs mentioned
was similar. Recommendations alongside pharmaceutical
medicines were also very common. There were protocolsin place in all pharmacies to promote this, and this prac-
tice was seen as providing considerable health benefits to
the customer:
‘I’d use it as a first line too, but I’d say that probably
80-90% would be as a combination. . . you give them
what they’ve asked for, and then you add in something
that will actually help them.’
The Group 3 pharmacists agreed that recommending
companion products provides a holistic solution, what-
ever those products might be:
‘. . .it’s about health outcomes. It’s not about selling
products for the sake of selling products. If you’ve
got a really bad dermatitis, it’s no good just giving
you a tube of cream. We’ve got to give [companion
products]. So it’s about a . . . healthcare solution.
Now if I just gave you that tube of ointment, it
might clear it up today, but it would be back
tomorrow, [but] if we’d sold the three products at
once there’s every chance that will never recur,
and you can keep it under control. The patient’s
happy as Larry, and it will have cost them less as
well.’
A preference for a CM over a pharmaceutical was
reported by several respondents:
‘. . .pain medications with tension headaches. You get
a lot of that. . .from computer use. . . so I get them onto
a magnesium supplement. . .. and the number of
people who will come back within three days and say
“that’s the first time I’ve never taken Mersyndol in my
life and I’m just ecstatic!”’
Like the pharmacists in Groups 1 and 2, Group 3
respondents wanted good quality evidence, and they felt
confident in the evidence they had found:
‘. . .say a medication is depleting something in the
system, say your statins and your CoQ10s. . .
everything that’s evidence-based.’
This group had similar opinions to Group 2 about the
importance of the profile of the company and the quality
of its products:
‘I think you do have a level of safety. . .a brand like
[mentions three brands] are the brands that have a lot
to lose, if they bring out dodgy products into the
market. A company that has only one item, they have
to work a lot harder to convince me to recommend
that product.’
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selling something just for the sake of selling something.
You’re selling a product you believe in.’
Barriers to the recommendation of CMs
There were more similarities between groups when it came
to the reasons given for not recommending CMs. The major
barrier for all groups was safety concerns around patients
on multiple medications or with complex health issues, and
the perceived need for those patients to seek medical advice
before adding a CM to their list of medications:
‘[I wouldn’t recommend to] people that are on a lot of
things already. I wouldn’t tell them to take it, unless
they’ve spoken to the doctor about it as well. . .’
‘. . . if they’re on something that has a narrow
therapeutic index, like chemo medications, etc., I’d
probably recommend them not to take it [CMs]. . . and
the other one is pregnancy, because there’s a lot of
CMs that don’t have safety data. . .’
Group 1 mentioned a lack of knowledge regarding efficacy
and safety of a product as a major disincentive:
‘. . . even if I know it works, if I don’t know if it’s OK
with all the other stuff they’re taking, I can’t
recommend it.’
Group 2 stressed the importance of evidence, and con-
sistently mentioned that if this is insufficient, they would
not recommend CMs:
‘If there was no evidence behind, I wouldn’t actively
recommend it.’
They described their position as one where patient
benefit outweighed any profit motive, and they were
disinclined to recommend a CM if the patient benefit
was not clear:
‘I’m very hesitant to put them on something that doesn’t
benefit them, that just benefits the business. . . it’s an
ethical stance that every pharmacist should have. . ..’
They generally had a low opinion of what may be
described as ‘fad’ products:
‘They want the magic weight loss thing they saw on
“Today Tonight” last night, and I think. . ..hang on. . ..
what was it? What rubbish. . ..’
All Group 2 respondents said they wouldn’t recom-
mend ‘fad’ products but the majority had these productsin their pharmacies and believed the customer had a
right to choose them:
‘If there was a fad product and there was a consumer
demand for it, of course we have to provide for that
consumer demand, but if there was no evidence
behind, I wouldn’t actively recommend it.’
Group 3 identified fewer barriers to the recommenda-
tion of CMs, but were also uncomfortable with ‘fad’ pro-
ducts and had some ethical concerns about their
presence in a pharmacy. This group expressed that they
would be likely to talk someone out of buying such a
product, if they were asked their opinion:
‘We don’t sell charlatan-type products. . . let’s have
some evidence-based stuff. . .that sort of thing tends to
be bad for the industry as a whole.’
Three out of the four respondents in this group said
that a lack of time was an issue:
‘. . .we’re under pressure with time. . .. . .if you stop the
next person from being served, because you’re having
an extra thirty seconds with someone, who should
have been a pretty in and out sort of transaction or
interaction, that next person becomes annoyed.’
Attitude to CMs
Attitudes relating to the value of CMs and to the role of
the pharmacist in relation to the use and integration
of CMs into pharmacy practice were well delineated
between groups. All agreed, however, that pharmacists
had a responsibility to provide information to customers
about any possible safety issues, such as interactions with
pharmaceutical medicines and contraindications.
Group 1 felt CMs had a role to play in terms of health
outcomes, but were less inclined to embrace a greater
integration of CM into pharmacy practice and did not
see it as their role to make CM recommendations.
Group 2 saw a growing role for CMs in pharmacy, but
were divided on whether it was the role of a pharmacist
to recommend them. Most saw the provision of CM
advice as adding value to what they could offer to facilitate
positive health outcomes, and in doing so gain loyalty
from their customers. When asked if they thought CM
was going to play a larger role in pharmacy in the future,
they were clear that they thought it would:
‘Yes, I think so, yes. It’s got a big role to play.’
Group 3 were very clear that there is an important and
growing role for CMs in pharmacy. They said their
customers expected them to be able to advise on which
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Group 2 who found it an important aspect of the service they
provide and saw it as ‘the area. . .to focus on in pharmacy
in the future’.
Education and resources
All but one of the respondents stated they did not
receive much CM training during their pharmacy degree
All said that they had learnt more about CM from their
day-to-day work experience than from their university
education or any other source. Questions regarding the
adequacy of CM topics in the pharmacy curriculum and
whether there should be more of it, provoked differing
responses.
Group 1 was, overall, not unhappy with their educa-
tion in terms of CM. They felt it was not comprehensive
and did think it may be useful to incorporate a greater
CM component to assist with patient queries:
‘It was a good foundation. . .it would have been useful,
I suppose, to do one semester unit on complementary
medicines, particularly for people going into
community pharmacy.’
One respondent found the desire to learn more was
based upon customer demand:
‘People come in and ask you about it all the time, so
you can’t exactly not know about it.’
Group 2 was somewhat more enthusiastic about in-
creasing the level of CM education. They saw this as an
advantage to their practice, and one respondent com-
mented that pharmacy students do not become aware of
potential benefits until they work in a pharmacy:
‘Yes, I do [think CM education should be
incorporated]. . ..If they don’t work in a pharmacy, they
don’t realise how much it can influence their scripts
and doing a service for the customer and delivering
holistic health benefits.’
One Group 2 respondent was rather more sceptical
about the acceptance of CM by the pharmacy establish-
ment:
‘I think the way pharmacy is, I doubt whether they
would [integrate CM]. . ..they’ve been brainwashed to
the point that they don’t want to know about that
stuff.’
Group 3 respondents were the most enthusiastic
about further integration. They saw benefits in pa-
tient care but also mentioned professional obligationssuch as the need to gain Continuing Professional
Development/Education (CPD/CPE) points and medi-
cation profiling responsibilities (guidelines for medi-
cation profiling services have been developed by the
Pharmaceutical Society of Australia to assist custo-
mers and their healthcare team in the safe and most
effective use of medications [24]):
‘There’s a big need for pharmacists to get educated, so
they know about interactions and also the drug
profiling that’s coming into pharmacy, that we’re all
going to be expected to do.’
Information sources used for CMs varied between
groups. Those in Group 1 described rarely feeling a need
to look something up. If they did, they tended to use
traditional sources such as medical journals, pharmacy
trade journals and medical websites. One pharmacist
would ask the naturopath who worked in their store.
They generally described the data as not compelling:
‘It’s very hard to expand the products that you like to
recommend based on evidence, because there’s not
always that much out there.’
Those in Group 3 used a wider range of resources,
including ones dedicated solely to CM, such as
herbal medicine and nutrition textbooks and com-
puter databases such as Hyperhealth [25]. They also
used information provided by companies and more
traditional sources such as pharmacy and medical
journals, MIMS (www.mims.com.au) and the Austra-
lian Medicines Handbook (www.amh.net.au). They
would also ask a naturopath, if one worked in their
store. They described a large amount of information
as being available:
‘. . ..and a lot more information is coming through to
us in pharmacy. There’s quite a few different
sources. . .The [Pharmacy] Guild will put out notices,
Pharmacy Daily. . ..so there’s a lot more of that
succinct information, you can then delve into more
detailed information if required.’
Those in Group 2 also described using a variety of
sources, such as MIMS, the Australian Medicines Hand-
book and information provided by companies, but rarely
used herbal or nutrition textbooks.
All respondents described a preference for information
to be presented concisely, with a brief description of the
medicine, benefits, dosage, contraindications/cautions
and a fully referenced research summary. The majority
stated that they did not have time to digest large amounts
of information and strongly preferred a summary.
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Of the sample (n=12), nine respondents regularly took a
CM (usually daily). In Group 1, two out of three took a
CM, and none reported a family background of CM use.
In Group 2, three out of five took CMs and only one
had a family background of CM use (Traditional Chinese
Medicines). They said that this probably had some in-
fluence on their openness to CM. In Group 3, all four
respondents used CMs. Two had some family back-
ground, where the family had used multivitamins or
other basic vitamin preparations, but none said that
influenced their current recommendation patterns. One
Group 3 member stated their interest had come about
because in the past, family members had achieved no
benefits from orthodox medicines, so they had looked
elsewhere to find answers.Relationship with other healthcare professionals
Most respondents described a somewhat uncomfortable
relationship with doctors. Only one pharmacist reported
a very positive relationship. This respondent had worked
in a pharmacy adjacent to a surgery, where doctors
commonly recommended CMs, and this had caused the
pharmacist to become more interested in the benefits of
CMs. Several pharmacists in Groups 2 and 3 said some
doctors were not happy with them recommending CMs
to their patients and recalled instances where a doctor
had told their patients not to take them. This was of
concern to the pharmacists and caused tension between
the two professions:
‘That can be frustrating, and subconsciously it can
form a bit of mistrust between myself and the
customer; when I’ve recommended something and the
doctor has said, “don’t take it”. I worry about that
sometimes.’
Communication between doctors and pharmacists was
regarded as poor, and several respondents thought that
doctors should become better educated about CMs for
improved patient care.
‘I think if they had a broader understanding, that
would benefit everyone.’
Many of the respondents had worked alongside a
naturopath – all pharmacists in Group 3, one in Group
2 and one in Group 1. Those who had were all very
positive about the value of having a naturopath in the
pharmacy. They consistently mentioned referring custo-
mers to the naturopath, if they did not feel adequately
knowledgeable, and learning from them about efficacy,
safety and interactions relating to CMs:‘The naturopath can keep right up to date and the
pharmacist can feed off that and learn from the
naturopath.’
Discussion
Previous research investigating the integration of CMs
into pharmacy practice has not examined in detail the
factors that impact the decision of a pharmacist to
recommend a CM product to a customer. This study
has identified a range of influential factors, including
pharmacy protocols relating to companion selling of
CMs; the desire to provide health benefits to a customer;
the pharmacist’s knowledge about CMs, which is linked to
confidence in recommending based on efficacy and safety;
awareness of evidence in support of CMs; the presence of
a naturopath in the store (an increasingly common
phenomenon in Australian pharmacies [26]); customer
demand and positive feedback from customers; and the
quality of products available and profile of the company
providing them (Table 2).
Previous studies have reported the primary reason for
patients choosing or being recommended a CM product
is for particular health benefits – the maintenance of
general health, prevention of disease and the treatment
of minor conditions [7,8,13]. This correlates with the
findings of this study, that patient benefit from CMs was
a major motivating factor for pharmacists in all groups.
The concept of providing a health benefit differed
somewhat between Group 2 and 3 respondents. Those
in Group 2 were more likely to accept that a CM could
offer health benefits if they were satisfied with the
evidence provided, whether by a company or by inde-
pendent sources, or if they had witnessed the benefit
themselves. This concurs with previous studies that have
found that knowledge of a particular CM and a proven
mechanism of action are influential factors [6,7]. In con-
trast, Group 3 respondents (those who recommended
CMs most frequently) were passionate about a ‘holistic
approach’ and commonly linked health benefits with a
‘healthcare solution’ comprising not only a specific treat-
ment, but also the provision of supportive measures to
prevent recurrence and thereby improve patient care.
This in turn was seen to be linked to business benefits.
All Group 3 respondents were owners or managers of
their stores, which may have influenced their emphasis
on business-related benefits. Previous research has
reported that profit is not an important motive for
pharmacists [6,7,15], although there is an understand-
ing that CM products are an important contributor to
the business of pharmacy [16].
The provision of a ‘healthcare solution’ or adopting a
‘holistic approach’ was mentioned by the majority of
Group 2 and 3 respondents. For most, this involved the
practice of recommending a CM as a companion
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several products with a view to providing the best patient
care. This professional behaviour of pharmacists has only
recently been described. A 2010 Australian survey investi-
gating the integration of CMs into pharmacy practice
found that nearly half of the respondents described their
practice as providing ‘integrative care’, which was defined
as ‘recommending CMs together with conventional
medicines as part of standard practice’ [16].
In banner pharmacies, the implementation of pro-
tocols for companion recommendation appeared to
be a major driver of the recommendation of CMs.
The four Group 2 respondents who worked in ban-
ner pharmacies all mentioned corporate companion
selling protocols as a major driver. Group 3 respon-
dents had all been instrumental in implementing such
protocols in their stores; they embraced this approach
in order to provide good customer service, and said it
provided them with a feeling of job satisfaction. The role
of companion selling protocols as a driver of recommen-
dation of CMs by pharmacists has not previously been
described. The existence of such protocols may cause
pharmacists to feel compelled to learn more about CMs
and in turn result in increased recommendation of CMs.
It also raises the question to what extent the professional
judgment of the pharmacist may be influenced by a proto-
col when deciding whether or not to recommended CMs
to a customer.
Questions of whether the relationship with other
healthcare professionals affected the recommendation of
CMs provided some interesting insights. All but one
respondent articulated either a neutral (n=4) or strained
(n=4) relationship with doctors. The main contentious
issue, identified by four respondents, was doctors
dissuading patients from taking a CM that the pharmacist
had recommended. The pharmacists were unhappy
with this situation and claimed it was a difficult situ-
ation to deal with, as the communication between the
two professions was poor.
The relationship with naturopaths was described as far
more harmonious. Naturopaths were seen as being able
to provide good quality information and were considered
to be a valuable resource in the pharmacy. Five respondents
worked alongside a naturopath, and one of these stated
that because a naturopath was present, they would refer
customers to the naturopath for a CM recommendation,
rather than make it themselves. Three Group 3 respon-
dents, who were store managers and had employed natur-
opaths, felt that the presence of a naturopath had not
changed their recommendation behaviour, although they
would often refer to the naturopath for more information
about a CM. A previous Australian survey found that
pharmacists who work alongside naturopaths find the
service provided by naturopaths valuable, while thepresence of a naturopath made pharmacists less likely to
recommend CMs themselves [16].
Barriers to the recommendation of CMs were relatively
clear-cut, with safety concerns (drug interactions and
adverse effects) being the most important, identified by all
respondents. Other identified barriers varied between
groups. Group 1 felt inadequately trained. Group 2
reported a lack of evidence as a significant factor and felt
the need to be confident in the patient benefit before
recommending a CM. Group 3 respondents were the only
to mention a lack of time as a reason for not recommending
CMs. This may be because they also wanted to offer a
more comprehensive ‘healthcare solution’, which no
doubt takes some time to provide. Previous studies
have identified a lack of knowledge or lack of evidence
as the main barriers to recommending CM products
[4,6,11,16-20,27]. As many pharmacists by their own
admission do not have adequate training in CM, it is
unclear whether in some cases they have truly assessed
the evidence for a CM before reaching the conclusion
that there is a lack of it.
All groups expressed discomfort with ‘fad’ products,
and respondents claimed they would not recommend
them if asked their opinion, while maintaining that
customers have a right to choose such products, and
thus they should be available from the pharmacy.
Conversely, respondents considered some CM companies
to be trustworthy and providing good quality and properly
researched CM products. The trusted companies were
considered to be the larger, more established ones with
larger products ranges. Previous research has also found
that poor product quality is a disincentive to recommend
CMs [16].
There was an impetus to learn more about CMs,
especially in Groups 2 and 3, which is encouraging,
as the majority of Australian pharmacy customers expect
the pharmacist to be able to provide accurate CM informa-
tion [5]. Respondents consistently reported that customers
are becoming more educated, are interested in preventative
approaches and want to take more control of their health-
care, a picture also reported from Canada in the context of
CM customers in pharmacies [28]. Therefore, significant
motivating factors for Group 2 respondents to increase
knowledge about CMs were likely the encouragement
to follow pharmacy protocols for companion selling,
customer demand and positive customer feedback.
The respondents seemed moderately satisfied with
the CM educational materials available but did find
room for improvement, both in terms of quality and
presentation of the information. They preferred brief
but professionally produced information that reflects
similar resources for pharmaceuticals, including easily
accessible online databases, which is consistent with
the suggestion that evidence-based CM information
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guidelines for pharmacists [16]. Interestingly, respon-
dents in this study were also happy to get information
from CM companies, as long as it is professionally pre-
sented with a clear description of levels of evidence to
support efficacy.
A Canadian study has highlighted the professional and
ethical dilemma faced by pharmacists who sell CMs
without possessing sufficient knowledge about these
products [29], and most respondents in the present study
saw a clear need to incorporate more CM education into
formal pharmacy training. Whilst there are some moves
to do so [30,31], there seems to be ample evidence from
this and other studies that the majority of pharmacists
would like more CM training [4,6,8,16,27,32,33].
Limitations
As with all studies relying on volunteer subjects, some
degree of selection bias is likely, and our small sample is
therefore unlikely to be truly representative of the
population of community pharmacists in Australia. In
particular, it may have been the case that pharmacists
with a greater interest in CM would have been more
likely to agree to take part in the study.
Another source of potential bias is that the primary
investigator (SEC), who conducted the interviews, is an
employee of a CM company, a fact the respondents were
aware of. This dual role of the investigator could poten-
tially have biased responses in favour of CM, but the
desire of study subjects to please the investigators is
always a potential source of bias, and we do not believe
that this would have influenced responses in a significant
way.
Although the small sample size and the above caveats
clearly limit the generalisability of the findings, it is
noteworthy that data saturation was reached, with no
new themes emerging in the final interviews. This, com-
bined with the in-depth nature of the interviews, allows
for this study to make a valuable contribution to the
understanding of the evolving interface between comple-
mentary medicine and pharmacy, in particular in
Australia. It should also provide a sound basis for a
larger qualitative study in the area.
Conclusions
This study has explored the factors that affect Australian
community pharmacists’ behaviour in terms of recom-
mending CMs to customers. These factors are clearly
many and diverse, and pharmacists’ knowledge of, confi-
dence with and inclination to recommend CMs vary.
We have for the first time described protocols for com-
panion selling of CMs as an important driver of the
recommendation of CMs, especially for pharmacists
working in banner stores. This is an important finding,because it suggests that corporate pharmacy groups
currently play a significant role in how many Australian
pharmacists recommend CMs to their customers.
Due to the widespread use of CMs by the Australian
public and the fact that many of these products are sold
in pharmacies, improving education for pharmacists in
this area is important. In line with many previous studies,
we found that most pharmacists feel ill prepared to
provide the public with adequate advice about the many
CM products in their stores. Improving CM education
ought to be a priority for all providers of pharmacy
training, and continuing professional education materials
and other information resources, whether produced by
industry or independent agencies, must be rigorous, of
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